Tuesday, Oct 20, 2020 | Last Update : 03:41 AM IST

195th Day Of Lockdown

Maharashtra1443409114960338084 Andhra Pradesh7192566588755981 Karnataka6406615157829286 Tamil Nadu6088555529389653 Uttar Pradesh4031013468595864 Delhi2827522506135401 West Bengal2603242287555017 Odisha222734190080912 Kerala204242131048772 Telangana1992761701091163 Bihar178882164537888 Assam169985139977655 Gujarat1332191132403417 Rajasthan1288591077181441 Haryana1237821059901307 Madhya Pradesh117588932382207 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  India   All India  10 Sep 2020  DCGI issues notice to Serum Institute over AstraZeneca's trial suspension

DCGI issues notice to Serum Institute over AstraZeneca's trial suspension

THE ASIAN AGE. | ASIAN AGE WEB DESK
Published : Sep 10, 2020, 10:29 am IST
Updated : Sep 10, 2020, 10:29 am IST

DGCI sought an immediate reply, saying else "it shall be construed that you have no explanation to offer and action will be taken"

 Serum Institute gets DCGI notice over Oxford COVID-19 vaccine trial suspension by AstraZeneca abroad. (AFP Photo)
  Serum Institute gets DCGI notice over Oxford COVID-19 vaccine trial suspension by AstraZeneca abroad. (AFP Photo)

The Drugs Controller General of India issued a show-cause notice to the Serum Institute of India for not informing it about AstraZeneca suspending the clinical trials of the Oxford vaccine candidate for COVID-19 in other countries and and also for not submitting casualty analysis of the "reported serious adverse events"

The notice was issued following reports that human trials of the most promising COVID-19 vaccine candidate, being developed by the University of Oxford, have been put on hold after a UK participant had an adverse reaction to it.

 

Dr V G Somani, Drugs Controller General of India, in his show-cause notice has asked SII as to why the permission granted for conducting phase 2 and 3 clinical trials of the vaccine candidate in the country be not suspended till patient safety is established.

"Whereas, Serum Institute of India Pvt Ltd, Pune, till now has not informed the central licensing authority regarding pausing the clinical trial carried out by AstraZeneca in other countries and also not submitted casualty analysis of the reported serious adverse event with the investigational vaccine for the continuation of phase 2 and 3 clinical trials of the subject vaccine in the country in light of the safety concerns," said the show-cause notice.

 

"In view of the above, I Dr V G Somani, Drugs Controller General of India and Central Licensing Authority hereby give you an opportunity to show cause as provided under rule 30 of the New Drugs and Clinical Trials Rules, 2019, why the permission granted to you August 2 shall not be suspended till patient safety is established," the notice further said.

The DGCI sought an immediate reply, saying else "it shall be construed that you have no explanation to offer and action deemed fit will be taken against you".

Meanwhile, SII which has partnered with AstraZeneca for manufacturing the Oxford vaccine candidate for COVID-19, said it is continuing with the trials in India.

 

Commenting on the recent reports on AstraZeneca halting the trials in the UK, SII said in a statement, "We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon."

Tags: dcgi, coronavirus, covid-19, vaccine, pharmaceutical, astrazeneca